Sam Kongsamut

Vice President, Business Development at Bioinvenu Corporation

Sam Kongsamut's Professional Contact Details

Email (Verified)

****@bioinvenu.com

Get Email Address

(973) 585-6777

Location

New York, New York, US

Company

Bioinvenu Corporation

Person Seniority

Person Functions

business development

Sam Kongsamut's Current Company Details

Bioinvenu Corporation

East Hanover, New Jersey, US • 2 Employees

biotechnology

BioInvenu is dedicated to develop assay products and services by utilizing a novel cell-based protein-protein interaction assay technology, LinkLightâ„¢ technology. The LinkLightâ„¢ technology was originally invented in Sanofi-Aventis. The technology utilizes protein-protein interactions as the functional signal readout. Protein-protein interaction is an essential cellular process regulating signal transductions in a living cell. Specific protein-protein interactions define signal transduction pathways. Ligand-induced transient protein-protein interactions are therefore of particular interests as the intervention points for drug discovery. The LinkLightâ„¢ technology has been applied to G-protein coupled receptors (GPCR), nuclear hormone receptors (NHR), and receptor tyrosine kinases (RTK) by utilizing receptor and its signal adaptor interaction as the functional signal readout. Biologically relevant compounds that modulate protein-protein interactions can be identified with this highly sensitive, specific and robust assay method. The technology has the potential for applying a broad range of drug targets that are difficult to tackle by existing methods. In additional for finding molecules that modulate protein-protein interaction signal cascades, the technology can be applied to protein-protein interaction drug targets by identifying molecules directly blocking protein-protein interactions.

Founded Year

2010

Organization Website

bioinvenu.com

Organization Languages

English

Organization Revenue

1400

Current Technologies

google analytics

wordpress org

mobile friendly